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MANAGEMENT OF EPILEPSY 

Anthony Galea Debono 
Figures for the incidence of epilepsy in 
Malta are not available. The overall figure 
for epilepsy given by the Royal College of 
General Practitioners (Reid 1960) is 4.82 
per 1,000 population. As there is no reason 
to expect any difference in the incidence in 
these Islands, one can expect that there are 
at least 1,500 epileptics in Malta. This 
would mean that all general practitioners 
would, at some time, come across a patient 
with epilepsy. 
Before considering the various drugs avail­
able for the treatment of epilepsy, it is 
worth highlighting the following points. 
Epilepsy is not one homogeneous condition, 
but many. 
Some patients with epilepsy have very in­
frequent attacks while others may have a 
considerable number of attacks per day. 
The latter group may prove to be more 
difficult to control. 
While on the one hand it is common practice 
not to treat with anti-convulsants patients 
who have had a solitary fit, there is some 
suggestion on the other hand that early 
treatment of fits prevents epilepsy from 
becoming chronic. Lcnnoxin 1960[1] stated 
that a seizures in the space of6 months was 
about all that one should tolerate before 
starting drug therapy. 
Once a decision is taken that a patient 
needs treatment, one has a number ofdrugs 
to choose from. Current opinion today 
favou rs the use ofone drug alone and to use 
it efficiently (Shorvon et al 1978) [2] and 
(Chadwich et al) [3]. 
PHENOBARBITONE 
This was the first effective anti-convulsant 
and has been in use since 1912. Today this 
drug has, by and large, been superseded by 
others and I tend to use it very little in my 
practice. 
There is no doubt that Phenobarbitone is 
effective in controlling tonic-clonic seizures. 
However, it has a high failure rate in con­
trolling partial seizures. The only advan­
tages that Phenobarbitone has over other 
drugs are the minimal gastro- intestinal 
side-effects and its low cost. Dose-related 
side- effects include drowsiness, ataxia, 
lethargy and slurred speech. Idiosyncratic 
side-effects include hyperactivity, altered 
mood, impaired cognitive function, altered 
calcium metabolism and skin rashes. Meas­
urement of serum levels is helpful mainly 
to check on patient's compliance; otherwise 
the clinical value of such estimations is 
limited. 
PRIMIDONE (MYSOLINE). 
This is metabolised by the liver into two 
active components, namely phenobarbitone 
and phenylethylmalonamide (PEMA). 
There is some evidence that both unchanged 
Primidone and PEMA have some anti-con­
vulsant activity in their own right. If, 
however, the major anti-convulsant activ­
ity of Primidone is due to the derived Phe­
nobarbitone, then there is little advantage 
in using Primidone rather than Phenobar­
bitone. From clinical studies (Mattson et al 
NEJM) [4], Primidone is equally effective 
as Phenobarbitone in controlling tonic-clonic 
seizures, and equally ineffective in control­
ling partial seizures. There is little clinical 
use in measuring serum levels other than 
to check on compliance. 
PHENYTOIN (EPANUTIN) 
Nowadays, Phenytoin is very often used as 
first line treatment. It is equally effective 
in controlling tonic-clonic seizures as Phe­
nobarbitone, but superiorto Phenobarbitone 
as regards partial seizures. The pharma­
cokinetics of Phenytoin are today very well 
understood. The drug has a long half life, 
and the whole dose can therefore be given 
once daily to adults and twice daily to chil­
dren. This no doubt improves patients' 
compliance. Measurements of serum levels 
are mandatory, owing to the fact that the 
relationship between the serum level con­
centration and the dose administered is an 
exponential one; and therefore small incre­
ments in the dose could produce toxic lev­
els. For this reason one is advised to in­
crease the .dose by 50 mg. increments each 
time when necessary. Once a steady state 
is achieved and Phenytoin is used as sole 
medication, serum levels need not be meas­
ured more than once yearly. Serum meas­
urements again become mandatory if the 
brand of Phenytoin is changed. Dose-re­
lated side-effects included nystagmus, dip­
lopia, ataxia, nausea, vomiting and drowsi­
ness. One has to enquire about these 
symptoms and look for the appropriate signs 
at routine follow-up. Idiosyncratic effects 
include acne, rash, gingival hyperplasia, 
megaloblastic anaemia, bone marrow de­
pression, abnormal results of liver function 
tests, altered calcium metabolism and hir­
sutism. If these side-effects occur, the drug 
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fects occur frequently (22%) (Mattson et al) 
[4] and therefore one tends to avoid this 
drug in children, adolescents and women. 
An advantage ofPhenytoin is definitely its 
low cost as compared to that of other major 
anti-convulsants. 
Phenytoin is the drug of first choice in an 
adult who presents with tonic-clonic sei­
zures or partial seizures. 
CARBAMAZEPINE (TEGRETOL) 
Since its introduction for use in epilepsy in 
1963, this agent has become an eminent 
first line management drug mainly due to 
its low toxicity and simplicity of use. The 
only significant disadvantage is its high 
cost. Today with the introduction of the 
Controlled Released Tegretol, twice daily 
medication is possible, and this will defi­
nitely enhance compliance. 
Carbamazepine is introduced at a low dose, 
and then steady increments in dose are 
made at weekly intervals, until a maxi­
mum of 1,600 mg. daily is reached. Very 
often much lower doses may be sufficient. 
The importance of gradual increments in 
dosage is to reduce the incidence of early 
side-effects which are nausea, drowsiness, 
ataxia and dizziness. Other dose-related 
side- effects are nystagmus, diplopia, 
blurred vision and headaches. Idiosyn­
cratic side-effects include transient leu­
kopenia, rash, fluid retention and very 
uncommonly aplastic anaemia. 
Carbamazepine is slightly more effective 
than Phenytoin or Phenobarbitone in con­
trolling generalised tonic-clonic seizures; it 
is about 3 times more effective than Pheno­
barbitone and twice more effective than 
Phenytoin in controlling partial seizures. 
(Mattson et al) [4]. Carbamazepine also 
had the lowest incidenceofside-effects when 
compared to Phenobarbitone, Phenytoin 
and Sodium Valproate used as monother­
apy. The figures for drug withdrawal in 
childhood because of side-effects, are as 
follows:-
Phenobarbitone 30%; Phenytoin 23%; 
Sodium Valproate 15%; and Tegrctol 8% 
(Forsythe and Sills) [5]. 
Determination of serum levels for Car­
bamazepine would not appear to be very 
useful clinically. Clinical assessment and 
observationoffit reduction wouldbe enough . 
Carbamazepine is one of the major anti­
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convulsants (although it does not help all 
patients). It is to be considered first line 
management for generalised tonic-clonic 
seizures in children and women of child­
bearing age, and for all patients with simple 
seizures and partial seizures with complex 
symptomatology (Le. Temporal Lobe Epi­
lepsy). 
SODIUM VALPROATE (EPILIMl 
This was introduced in 1974 and is today 
considered as one of the three main line 
therapeutic agents (Le. with Phenytoin and 
Carbamazepine). Sodium Valproate has a 
"broad spectrum" of anti- epileptic activi­
ties in adults and children. It is generally 
well tolerated. Dose-related side-effects 
include nausea, vomiting, weight gain, 
tremor, anorexia, indigestion, and heart­
burn, while idiosyncratic side-effects in­
clude rash, bone marrow depression, hepa­
totoxicity, alopecia and pancreatitis and 
rarely amenorrhoea. Dosage schemes are 
simple: in adults treatment is started at a 
dose of 200 mg. twice daily, with regular 
increments up to a maximum of 2,600 log. 
daily, depending on clinical responses. In 
children, the maximum dose is 30 mg./Kg. 
per day. The introduction ofenteric coated 
Epilim has enabled the total daily dosage to 
be given in two divided doses, thereby en­
hancing compliance. 
There does not appear to be any necessity 
for routine serum estimation. This how­
ever may be useful when poor compliance 
or side-effects are suspected or when poor 
seizure control is present. Sodium Val­
proate was found to be equally effective as 
Phenytoin in adult onset epilepsy (Turn­
bull et al) [6) while Loiseau [7) concluded 
that Valproate was at least equally effec­
tive as Carbamazepine in controlling par­
tial seizures. Sato et al [8) concluded that 
Valproate was as effective as Ethozuximide 
in controlling petit mal attacks (Le. 3 cycle/ 
sec spike and wave discharges on E.E.G. 
with clinical accompaniments). Covanis et 
al [9) found that myclonic seizures were 
adequately controlled (84%) by Valproate. 
Finally Jeavons et al [10) concluded that 
Valproate will control up to 60% of Photo­
sensitive epileptic attacks. 
Valproate is therefore indicated as first line 
management in children and young males 
with generalized tonic-clonic seizures, petit 
mal, photosensitive and myoclonic epilepsy. 
Owing to recent reports of an association 
between neural tube defects and Valproate 
administration in pregnancy Valproate 
should perhaps be avoided in post-pubertal 
adolescent females and women ofthe child­
bearing age. 
ETHOSUXIMIDE (ZARONTIN) 
Ethosuximide together with Valproate is 
one of the two drugs of choice in petit mal. 
It is a relatively safe drug. Dose-related 
side-effects include nausea, vomiting, ano­
rexia, headache, fatigue, lethargy, dizzi­
ness and hiccups; while idiosyncratic side­
effects include, rash, blood dyscrasias, 
periorbital oedema, renal dysfunction and 
liver dysfunction. 
The usual dose ofEthosuximide is 750 mg. 
given in three divided doses. As tonic­
generalized seizures often co-exist with petit 
mal attacks, a second drug may have to be 
used together with Ethosuximide. In this 
situation, Epilim would be a superior drug 
to use as it is effective for both conditions. 
Blood level estimation is not particularly 
helpful clinically. 
CLONAZEPAM (RIVOTRIL) 
Clonazepam is a benzodiazepine derivative 
and is generally used as a second line treat­
ment for petit mal and generalized tonic­
clonic seizures. Dose-related side-effects 
include drowsiness, sedation, ataxia, hy­
peractivity and irritability; while idiosyn­
cratic side-effects include hypersalivation 
and increased bronchosecretion. 
WHEN SHOULD A SECOND DRUG 
BE INTRODUCED? 
Monotherapy, if used judiciously, can give 
very favourable results in a large number of 
patients. A second drug is to be added only 
ifcontrol has been unsatisfactory. One has 
to remember that treatment with more 
than one drug alters the pharmokinetics of 
individual drugs. Unsatisfactory control 
does not mean a one:aff seizure, or the 
occurrence of one seizure a year, where 
previously the patient was having up to 10 
per year or more. One must resist the 
pressures by patients or their relatives to 
change medication or add something new 
at this stage. 
WHEN SHOULD MEDICATION 

BE STOPPED? 

This is a difficult problem. It is not uncom­
mon to find patients who have been fit free 
for 20 years and are still on anti- convul­
sants! Generally speaking if the patient 
has been seizure- free for over 4 years, has 
had a normal E.E.G., and the attacks were 
not focal or due to an underlying organic 
lesion, and the patient did not have sei­
zures for a long time before control was 
achieved, then withdrawal of medication 
should be considered. This should be done 
gradually and over a long period of time, 
such as 12 months. The recurrence rate for 
children is about 1 in 4 while that in adults 
is 1 in 3. The advantages of stopping 
medication should be obvious, and these 
include unnecessary expense and eliminat­
ing the possible long-term side-effects of 
drugs, and in female patients because ofthe 
possibility of pregnancy. 
ANTI-CONVULSANT THERAPY 

IN PREGNANCY. 

Anti-convulsant therapy is essential in 
pregnancy, if the mother has active epi­
lepsy. Prolonged seizures may be more 
harmful to mother and foetus than the 
risks of anti-convulsants. While it is true 
that there is an incidence of neonatal mal­
formation of about 2 to 3 times the normal 
in babies of epileptic mothers on anti-con­
vulsants, no specific drug can be impli­
cated. These malformations include facial 
clefts, congenital heart disease, and mal­
formations oftheurogential system(mainly 
hypospadias). 
With the exception of Sodium Valproate, 
there is no reason to change pre-pregnant 
anti-convulsants. Monitoringofserum anti­
convulsants is helpful in pregnancy, as an 
upward dose adjustment may be necessary. 
An increase in bleeding tendency has been 
reported in pregnant epileptic women on 
anti-convulsants. This is presumed to be 
due to deficient formation of Vitamin K 
dependent coagulation factors. For this 
reason Vit.K. is given to the mother prior to 
delivery and to the baby at birth [11). 
Breast-feeding is not contraindicated in 
epileptic mothers on anti-convulsants. If 
epilepsy occurs for the first time in preg­
nancy, Carbamazepine is the treatment of 
choice. 
THE TREATMENT OF MAJOR 

STATUS EPILEPTICUS 

This is par excellence one of the more acute 
emergencies in neurological practice, with 
a mortality ofcirca 20% (Oxbury & Whitty) 
[12). Patients should be treated in an In­
tensive Care Unit. Therapy should be ad­
ministered intravenously in high doses, 
and repeated as necessary. 
Diazepam (Valium) is given in a dose oflO 
mg. i.v. over a 2 minute period, and usually 
terminates status. Higher doses however 
may be required in adults. (Children re­
quire smaller doses). Repeated doses may 
be essential. 
Chlormethiazole (Hemi nevrin) is next used 
if diazepam fails. This agent is given as an 
I.v. infusion of0.8% solution. The rate is to 
be adjusted according to clinical response. 
General anaesthesia and curarization is 
required if the above measures fail. 
The pre-status anti-convulsants should be 
continued, or, if the status occurred as the 
first manifestation of epilepsy, then 
Phenytoin or Carbamazepine should be 
started immediately, together with the 
above. 
Dr. Anthony Galea Debono M.D. MRCP. 
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